Sientra (SIEN) Earns Market Perform Rating from Analysts at Wells Fargo & Co

Wells Fargo & Co started coverage on shares of Sientra (NASDAQ:SIEN) in a research note released on Thursday morning, Marketbeat.com reports. The firm issued a market perform rating and a $9.00 price objective on the medical instruments supplier’s stock.

Several other analysts have also commented on SIEN. Zacks Investment Research upgraded shares of Sientra from a sell rating to a hold rating in a research report on Friday, November 16th. BidaskClub lowered shares of Sientra from a sell rating to a strong sell rating in a research report on Tuesday, December 18th. Maxim Group upgraded shares of Sientra from a hold rating to a buy rating in a research report on Wednesday, December 19th. ValuEngine lowered shares of Sientra from a strong-buy rating to a buy rating in a research report on Thursday, January 24th. Finally, William Blair lowered shares of Sientra from an outperform rating to a market perform rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $20.44.

SIEN stock opened at $8.84 on Thursday. The company has a market capitalization of $252.82 million, a PE ratio of -2.72 and a beta of -0.04. Sientra has a 12 month low of $7.74 and a 12 month high of $26.79. The company has a current ratio of 2.77, a quick ratio of 2.34 and a debt-to-equity ratio of 0.36.

Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.19). The business had revenue of $19.02 million during the quarter, compared to analyst estimates of $18.87 million. Sientra had a negative net margin of 121.28% and a negative return on equity of 123.50%. Equities analysts anticipate that Sientra will post -2.52 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Alliancebernstein L.P. boosted its position in Sientra by 18.8% during the third quarter. Alliancebernstein L.P. now owns 21,500 shares of the medical instruments supplier’s stock worth $513,000 after acquiring an additional 3,400 shares during the last quarter. Federated Investors Inc. PA boosted its holdings in shares of Sientra by 19,162.9% in the 3rd quarter. Federated Investors Inc. PA now owns 66,457 shares of the medical instruments supplier’s stock valued at $1,587,000 after purchasing an additional 66,112 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Sientra by 74.2% in the 2nd quarter. Northern Trust Corp now owns 270,559 shares of the medical instruments supplier’s stock valued at $5,278,000 after purchasing an additional 115,283 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Sientra in the 3rd quarter valued at $3,767,000. Finally, AQR Capital Management LLC boosted its holdings in shares of Sientra by 41.5% in the 3rd quarter. AQR Capital Management LLC now owns 19,345 shares of the medical instruments supplier’s stock valued at $462,000 after purchasing an additional 5,675 shares during the last quarter. Hedge funds and other institutional investors own 92.79% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Featured Story: How to find the components of the quick ratio

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.